💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dulaglutide

CHEMBL2108027 Phase 4 Approuvé Protein
Half-Life
5 days
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A long-acting GLP-1 receptor agonist injected weekly to improve blood sugar control in adults with type 2 diabetes. It also provides cardiovascular benefits and may promote weight loss.

Aires thérapeutiques

Cardiovascular Disease Bipolar Disorder Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Atrial Fibrillation

Classes de médicaments

A — A - Alimentary Tract and Metabolism

Mécanisme d'action

GLP-1 receptor agonist fused to Fc fragment; enhances glucose-dependent insulin secretion.

Pharmacokinetics (PK)

Half-Life 5 days

Pharmacodynamics (PD)

Mécanisme

GLP-1 receptor agonist fused to Fc fragment; enhances glucose-dependent insulin secretion.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A long-acting GLP-1 receptor agonist injected weekly to improve blood sugar control in adults with type 2 diabetes. It also provides cardiovascular benefits and may promote weight loss.

GLP-1 receptor agonist fused to Fc fragment; enhances glucose-dependent insulin secretion.

Key pharmacokinetic parameters for Dulaglutide: Half-life: 5 days.

Yes, Dulaglutide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

Related Drugs

Same Drug Class

Metformin Small molecule Omeprazole Small molecule Pantoprazole Small molecule Lansoprazole Small molecule
{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108027. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.